Roche's Lucentis Could Get Boost From House Compounding Directives To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Compounding pharmacies – and makers of particular products – would see favorable guidance changes under instructions to FDA in House appropriations report.
You may also be interested in...
Drug Compounding Can't Be Justified By Price, FDA Says
Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.
Eylea, Avastin Both Get A Boost From NIH Comparative Study In DME
The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.
Calculating Califf’s Course To Confirmation
Robert Califf got 89 votes in the Senate last time – but that’s also the least a Democratic nominee has ever gotten.